Meeting
2018 ASCO Annual Meeting
Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).
Authors
Daniel Olson
University of Chicago, Chicago, IL
Daniel Olson , Jason J. Luke , Sigrun Hallmeyer , Madhuri Bajaj , Timothy Carll , Thomas Krausz , Yuanyuan Zha , Theodore Karrison , Bruce Brockstein , Vernon K. Sondak , Zeynep Eroglu , Thomas Gajewski , Nikhil I. Khushalani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02743819
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9514)
DOI
10.1200/JCO.2018.36.15_suppl.9514
Abstract #
9514
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane
Poster
2018 ASCO Annual Meeting
Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
First Author: Yousef Zakharia
Poster
2018 ASCO Annual Meeting
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
First Author: Adil Daud
Poster
2017 ASCO Annual Meeting
ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.
First Author: Melissa Lynne Johnson